COX-2-765G>C Polymorphism Increases the Risk of Cancer: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Wang, Xiao feng ^a,c   Huang, Ming zhu ^a,c   Zhang, Xiao wei ^a,c   Hua, Rui xi ^b   Guo, Wei jian ^a,c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

ALLELE; ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; COX 2 GENE; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; LEUKEMIA; PANCREAS CANCER; RISK ASSESSMENT; STOMACH CANCER; SYSTEMATIC REVIEW;

CYCLOOXYGENASE 2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84883430320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073213     Document Type: Article

References (98)

1. Yaghoobi M, Rakhshani N, Sadr F, Bijarchi R, Joshaghani Y, et al. (2004) Hereditary risk factors for the development of gastric cancer in younger patients. BMC Gastroenterol 4: 28.
2. Berlau J, Glei M, Pool-Zobel BL, (2004) Colon cancer risk factors from nutrition. Anal Bioanal Chem 378: 737-743.
3. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V, (2012) Multifaceted link between cancer and inflammation. Biosci Rep 32: 1-15.
4. Mantovani A, (2005) Cancer: inflammation by remote control. Nature 435: 752-753.
5. Rubin DC, Shaker A, Levin MS, (2012) Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 3: 107.
6. Arzumanyan A, Reis HM, Feitelson MA, (2013) Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 13: 123-135.
7. Haghshenas M, Golini-Moghaddam T, Rafiei A, Emadeian O, Shykhpour A, et al. (2013) Prevalence and type distribution of high-risk human papillomavirus in patients with cervical cancer: a population-based study. Infect Agent Cancer 8: 20.
8. Hardbower DM, de Sablet T, Chaturvedi R, Wilson KT (2013) Chronic inflammation and oxidative stress: The smoking gun for Helicobacter pylori-induced gastric cancer? Gut Microbes 4.
9. Ekbom A, Helmick C, Zack M, Adami HO, (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228-1233.
10. Hussain SP, Hofseth LJ, Harris CC, (2003) Radical causes of cancer. Nat Rev Cancer 3: 276-285.
11. Wang MT, Honn KV, Nie D, (2007) Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 26: 525-534.
12. Cao Y, Prescott SM, (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286.
13. O'Byrne KJ, Dalgleish AG, (2001) Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 85: 473-483.
14. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, et al. (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716.
15. Szczeklik W, Sanak M, Szczeklik A, (2004) Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 114: 248-253.
16. Zhang XM, Zhong R, Liu L, Wang Y, Yuan JX, et al. (2011) Smoking and COX-2 functional polymorphisms interact to increase the risk of gastric cardia adenocarcinoma in Chinese population. PLoS One 6: e21894.
17. Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, et al. (2009) Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer 9: 407.
18. Balistreri CR, Caruso C, Carruba G, Miceli V, Campisi I, et al. (2010) A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications. Curr Pharm Des 16: 718-724.
19. Cox DG, Buring J, Hankinson SE, Hunter DJ, (2007) A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res 9: R3.
20. Liu JL, Liang Y, Wang ZN, Zhou X, Xing LL, (2010) Cyclooxygenase-2 polymorphisms and susceptibility to gastric carcinoma: a meta-analysis. World J Gastroenterol 16: 5510-5517.
21. Yu KD, Chen AX, Yang C, Qiu LX, Fan L, et al. (2010) Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 122: 251-257.
22. Dong J, Dai J, Zhang M, Hu Z, Shen H, (2010) Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis. J Gastroenterol Hepatol 25: 1042-1050.
23. Song Q, Zhu B, Hu W, Cheng L, Gong H, et al. (2012) A common SMAD7 variant is associated with risk of colorectal cancer: evidence from a case-control study and a meta-analysis. PLoS One 7: e33318.
24. Ma Y, Xu YC, Tang L, Zhang Z, Wang J, et al. (2012) Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol 1: 11.
25. Chen W, Zhong R, Ming J, Zou L, Zhu B, et al. (2012) The SLC4A7 variant rs4973768 is associated with breast cancer risk: evidence from a case-control study and a meta-analysis. Breast Cancer Res Treat 136: 847-857.
26. Ke J, Zhong R, Zhang T, Liu L, Rui R, et al. (2013) Replication study in Chinese population and meta-analysis supports association of the 5p15.33 locus with lung cancer. PLoS One 8: e62485.
27. Wei G, Ni W, Chiao JW, Cai Z, Huang H, et al. (2011) A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 4: 46.
28. Liu L, Yuan P, Liu L, Wu C, Zhang X, et al. (2011) A functional-77T>C polymorphism in XRCC1 is associated with risk of breast cancer. Breast Cancer Res Treat 125: 479-487.
29. Egger M, Davey SG, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
30. Liu L, Wu J, Wu C, Wang Y, Zhong R, et al. (2011) A functional polymorphism (-1607 1G->2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer 117: 5172-5181.
31. Duval S, Tweedie R, (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56: 455-463.
32. Tan W, Wu J, Zhang X, Guo Y, Liu J, et al. (2007) Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 28: 1197-1201.
33. Xing LL, Wang ZN, Jiang L, Zhang Y, Xu YY, et al. (2008) Cyclooxygenase 2 polymorphism and colorectal cancer:-765G>C variant modifies risk associated with smoking and body mass index. World J Gastroenterol 14: 1785-1789.
34. Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC, (2004) Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: the Singapore Chinese Health Study. Br J Cancer 90: 1760-1764.
35. Iglesias D, Nejda N, Azcoita MM, Schwartz SJ, Gonzalez-Aguilera JJ, et al. (2009) Effect of COX2-765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control 20: 1421-1429.
36. Gong Z, Bostick RM, Xie D, Hurley TG, Deng Z, et al. (2009) Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma. Int J Colorectal Dis 24: 647-654.
37. Wang J, Joshi AD, Corral R, Siegmund KD, Marchand LL, et al. (2012) Carcinogen metabolism genes, red meat and poultry intake, and colorectal cancer risk. Int J Cancer 130: 1898-1907.
38. Daraei A, Salehi R, Mohamadhashem F, (2012) PTGS2 (COX2)-765G>C gene polymorphism and risk of sporadic colorectal cancer in Iranian population. Mol Biol Rep 39: 5219-5224.
39. Cox DG, Pontes C, Guino E, Navarro M, Osorio A, et al. (2004) Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 91: 339-343.
40. Hoff JH, Te MR, Roelofs HM, van der Logt EM, Nagengast FM, et al. (2009) COX-2 polymorphisms-765G->C and-1195A->G and colorectal cancer risk. World J Gastroenterol 15: 4561-4565.
41. Pereira C, Pimentel-Nunes P, Brandao C, Moreira-Dias L, Medeiros R, et al. (2010) COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol 22: 607-613.
42. Hamajima N, Takezaki T, Matsuo K, Saito T, Inoue M, et al. (2001) Genotype Frequencies of Cyclooxygenease 2 (COX2) Rare Polymorphisms for Japanese with and without Colorectal Cancer. Asian Pac J Cancer Prev 2: 57-62.
43. Thompson CL, Plummer SJ, Merkulova A, Cheng I, Tucker TC, et al. (2009) No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol 15: 2240-2244.
44. Li Y, Dai L, Zhang J, Wang P, Chai Y, et al. (2012) Cyclooxygenase-2 polymorphisms and the risk of gastric cancer in various degrees of relationship in the Chinese Han population. Oncol Lett 3: 107-112.
45. Hou L, Grillo P, Zhu ZZ, Lissowska J, Yeager M, et al. (2007) COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population. Anticancer Res 27: 4243-4247.
46. Shin WG, Kim HJ, Cho SJ, Kim HS, Kim KH, et al. (2012) The COX-2-1195AA Genotype Is Associated with Diffuse-Type Gastric Cancer in Korea. Gut Liver 6: 321-327.
47. Liu F, Pan K, Zhang X, Zhang Y, Zhang L, et al. (2006) Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 130: 1975-1984.
48. Sitarz R, Leguit RJ, de Leng WW, Polak M, Morsink FM, et al. (2008) The COX-2 promoter polymorphism-765 G>C is associated with early-onset, conventional and stump gastric cancers. Mod Pathol 21: 685-690.
49. Pereira C, Sousa H, Ferreira P, Fragoso M, Moreira-Dias L, et al. (2006)-765G>C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol 12: 5473-5478.
50. Saxena A, Prasad KN, Ghoshal UC, Bhagat MR, Krishnani N, et al. (2008) Polymorphism of-765G>C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: a study from northern India. World J Gastroenterol 14: 1498-1503.
51. Bi N, Yang M, Zhang L, Chen X, Ji W, et al. (2010) Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res 16: 2383-2390.
52. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, et al. (2007) COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 97: 557-561.
53. Murad A, Lewis SJ, Smith GD, Collin SM, Chen L, et al. (2009) PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis. Prostate Cancer Prostatic Dis 12: 296-300.
54. Catsburg C, Joshi AD, Corral R, Lewinger JP, Koo J, et al. (2012) Polymorphisms in carcinogen metabolism enzymes, fish intake, and risk of prostate cancer. Carcinogenesis 33: 1352-1359.
55. Wu HC, Chang CH, Ke HL, Chang WS, Cheng HN, et al. (2011) Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in taiwan. Anticancer Res 31: 221-225.
56. Joshi AD, Corral R, Catsburg C, Lewinger JP, Koo J, et al. (2012) Red meat and poultry, cooking practices, genetic susceptibility and risk of prostate cancer: results from a multiethnic case-control study. Carcinogenesis 33: 2108-2118.
57. Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, et al. (2004) COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25: 961-966.
58. Kristinsson JO, van Westerveld P, Te MR, Roelofs HM, Wobbes T, et al. (2009) Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. World J Gastroenterol 15: 3493-3497.
59. Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B, (2009) Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma. Mutat Res 663: 52-59.
60. Zhang X, Miao X, Tan W, Ning B, Liu Z, et al. (2005) Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129: 565-576.
61. Moons LM, Kuipers EJ, Rygiel AM, Groothuismink AZ, Geldof H, et al. (2007) COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol 102: 2373-2379.
62. Bye H, Prescott NJ, Matejcic M, Rose E, Lewis CM, et al. (2011) Population-specific genetic associations with oesophageal squamous cell carcinoma in South Africa. Carcinogenesis 32: 1855-1861.
63. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, et al. (2005) PTGS2 (COX-2)-765G>C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14: 616-619.
64. Ueda N, Maehara Y, Tajima O, Tabata S, Wakabayashi K, et al. (2008) Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the Self Defense Forces Health Study. Cancer Sci 99: 576-581.
65. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, et al. (2006) Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15: 1126-1131.
66. Peters WH, Lacko M, Te MR, Voogd AC, Oude OM, et al. (2009) COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck 31: 938-943.
67. Ben NH, Chahed K, Bouaouina N, Chouchane L, (2009) PTGS2 (COX-2)-765 G>C functional promoter polymorphism and its association with risk and lymph node metastasis in nasopharyngeal carcinoma. Mol Biol Rep 36: 193-200.
68. Mittal M, Kapoor V, Mohanti BK, Das SN, (2010) Functional variants of COX-2 and risk of tobacco-related oral squamous cell carcinoma in high-risk Asian Indians. Oral Oncol 46: 622-626.
69. Chiang SL, Chen PH, Lee CH, Ko AM, Lee KW, et al. (2008) Up-regulation of inflammatory signalings by areca nut extract and role of cyclooxygenase-2-1195G>a polymorphism reveal risk of oral cancer. Cancer Res 68: 8489-8498.
70. Gao J, Ke Q, Ma HX, Wang Y, Zhou Y, et al. (2007) Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A 70: 908-915.
71. Piranda DN, Festa-Vasconcellos JS, Amaral LM, Bergmann A, Vianna-Jorge R, (2010) Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study. BMC Cancer 10: 613.
72. Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, et al. (2010) PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 31: 455-461.
73. Coskunpinar E, Eraltan IY, Turna A, Agachan B, (2011) Cyclooxygenase-2 gene and lung carcinoma risk. Med Oncol 28: 1436-1440.
74. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, et al. (2004) Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25: 229-235.
75. Liu CJ, Hsia TC, Wang RF, Tsai CW, Chu CC, et al. (2010) Interaction of cyclooxygenase 2 genotype and smoking habit in Taiwanese lung cancer patients. Anticancer Res 30: 1195-1199.
76. Hoeft B, Becker N, Deeg E, Beckmann L, Nieters A, (2008) Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma. Cancer Causes Control 19: 163-173.
77. Monroy CM, Cortes AC, Lopez MS, D'Amelio AJ, Etzel CJ, et al. (2011) Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes. Mol Carcinog 50: 36-46.
78. Chang ET, Birmann BM, Kasperzyk JL, Conti DV, Kraft P, et al. (2009) Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 18: 976-986.
79. Lira MG, Mazzola S, Tessari G, Malerba G, Ortombina M, et al. (2007) Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol 157: 49-57.
80. Cocos R, Schipor S, Nicolae I, Thomescu C, Raicu F, (2012) Role of COX-2 activity and CRP levels in patients with non-melanoma skin cancer.-765G>C PTGS2 polymorphism and NMSC risk. Arch Dermatol Res 304: 335-342.
81. Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, et al. (2007) Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 617: 138-146.
82. Wang CH, Wu KH, Yang YL, Peng CT, Wang RF, et al. (2010) Association study of cyclooxygenase 2 single nucleotide polymorphisms and childhood acute lymphoblastic leukemia in Taiwan. Anticancer Res 30: 3649-3653.
83. Zheng J, Chen S, Jiang L, You Y, Wu D, et al. (2011) Functional genetic variations of cyclooxygenase-2 and susceptibility to acute myeloid leukemia in a Chinese population. Eur J Haematol 87: 486-493.
84. Zhao D, Xu D, Zhang X, Wang L, Tan W, et al. (2009) Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology 136: 1659-1668.
85. Xu DK, Zhang XM, Zhao P, Cai JC, Zhao D, et al. (2008) [Association between single nucleotide polymorphisms in the promoter of cyclooxygenase COX-2 gene and hereditary susceptibility to pancreatic cancer]. Zhonghua Yi Xue Za Zhi 88: 1961-1965.
86. Agachan CB, Attar R, Kahraman OT, Dalan AB, Iyibozkurt AC, et al. (2011) Cyclooxygenase-2 gene and epithelial ovarian carcinoma risk. Mol Biol Rep 38: 3481-3486.
87. Pinheiro SP, Gates MA, DeVivo I, Rosner BA, Tworoger SS, et al. (2010) Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk. Int J Mol Epidemiol Genet 1: 320-331.
88. Chang WS, Yang MD, Tsai CW, Cheng LH, Jeng LB, et al. (2012) Association of cyclooxygenase 2 single-nucleotide polymorphisms and hepatocellular carcinoma in Taiwan. Chin J Physiol 55: 1-7.
89. He J, Zhang Q, Ren Z, Li Y, Li X, et al. (2012) Cyclooxygenase-2-765 G/C polymorphisms and susceptibility to hepatitis B-related liver cancer in Han Chinese population. Mol Biol Rep 39: 4163-4168.
90. Pandey S, Mittal RD, Srivastava M, Srivastava K, Mittal B, (2010) Cyclooxygenase-2 gene polymorphisms and risk of cervical cancer in a North Indian population. Int J Gynecol Cancer 20: 625-630.
91. Schwartzbaum J, Ahlbom A, Malmer B, Lonn S, Brookes AJ, et al. (2005) Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res 65: 6459-6465.
92. Biramijamal F, Basatvat S, Hossein-Nezhad A, Soltani MS, Akbari NK, et al. (2010) Association of COX-2 promoter polymorphism with gastrointestinal tract cancer in Iran. Biochem Genet 48: 915-923.
93. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, et al. (2002) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22: 1631-1636.
94. Zhu W, Wei BB, Shan X, Liu P, (2010)-765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 37: 277-288.
95. Zhang HT, Xu Y, Zhang ZH, Li L, (2012) Meta-analysis of epidemiological studies demonstrates significant association of PTGS2 polymorphism rs689470 and no significant association of rs20417 with prostate cancer. Genet Mol Res 11: 1642-1650.
96. Cao H, Xu Z, Long H, Li XQ, Li SL, (2010) The-765C allele of the cyclooxygenase-2 gene as a potential risk factor of colorectal cancer: a meta-analysis. Tohoku J Exp Med 222: 15-21.
97. Pereira C, Medeiros RM, Dinis-Ribeiro MJ, (2009) Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol 21: 76-91.
98. Liang Y, Liu JL, Wu Y, Zhang ZY, Wu R, (2011) Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: a meta-analysis. Tohoku J Exp Med 223: 137-144.